Free tool
FAERS Monitor: Femlyv
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218718 or its brand name (Femlyv, Ethinyl Estradiol, Norethindrone Acetate). Reports on generic versions are filed under their own applications.
Reports
8
Serious
7
88% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- breast cancer metastatic2
- abdominal pain1
- abnormal behaviour1
- breast cancer1
- contralateral breast cancer1
- dermatitis allergic1
- dyspnoea1
- endometrial hyperplasia1
- energy increased1
- mouth ulceration1
- oestradiol increased1
- palpitations1
- postural orthostatic tachycardia syndrome1
- pulmonary embolism1
- restlessness1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 3 |
| 2010 | 1 |
| 2016 | 1 |
| 2021 | 1 |
| 2025 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,151 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| contralateral breast cancer | 1 | 12837.9 | 2041.9 | 3,193 |
| oestradiol increased | 1 | 8772.6 | 1397.6 | 2,185 |
| endometrial hyperplasia | 1 | 3253.1 | 519.4 | 811 |
| postural orthostatic tachycardia syndrome | 1 | 1949.5 | 311.4 | 486 |
| breast cancer metastatic | 2 | 490.0 | 147.5 | 548 |
| energy increased | 1 | 445.5 | 71.2 | 110 |
| dermatitis allergic | 1 | 209.1 | 33.4 | 51 |
| mouth ulceration | 1 | 124.8 | 19.9 | 30 |
| restlessness | 1 | 71.8 | 11.5 | 17 |
| abnormal behaviour | 1 | 66.4 | 10.6 | 16 |
| breast cancer | 1 | 28.2 | 4.5 | 6 |
| pulmonary embolism | 1 | 27.7 | 4.4 | 6 |
| palpitations | 1 | 22.5 | 3.6 | 5 |
| abdominal pain | 1 | 11.3 | 1.8 | 2 |
| dyspnoea | 1 | 4.6 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.